Oriola Oyj
OMXH:OKDBV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (7.2), the stock would be worth €0.19 (82% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 39.1 | €1.06 |
0%
|
| 3-Year Average | 7.2 | €0.19 |
-82%
|
| 5-Year Average | 15.3 | €0.41 |
-61%
|
| Industry Average | 20.7 | €0.56 |
-47%
|
| Country Average | 17.9 | €0.48 |
-54%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
€101.6m
|
/ |
Jan 2026
€2.6m
|
= |
|
|
€101.6m
|
/ |
Dec 2026
€20.5m
|
= |
|
|
€101.6m
|
/ |
Dec 2027
€26.8m
|
= |
|
|
€101.6m
|
/ |
Dec 2028
€32m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| FI |
O
|
Oriola Oyj
OMXH:OKDBV
|
195.6m EUR | 39.1 | -7.2 | |
| US |
|
Mckesson Corp
NYSE:MCK
|
101.9B USD | 18.6 | 23.5 | |
| US |
|
Cencora Inc
NYSE:COR
|
59.9B USD | 16.6 | 36.9 | |
| US |
A
|
Amerisourcebergen Corp
LSE:0HF3
|
59.4B USD | 16.4 | 36.6 | |
| US |
|
Cardinal Health Inc
NYSE:CAH
|
47.2B USD | 17.9 | 28.4 | |
| AU |
|
Sigma Healthcare Ltd
ASX:SIG
|
32.1B AUD | 26.2 | 35.3 | |
| CN |
|
Shanghai Pharmaceuticals Holding Co Ltd
SSE:601607
|
62.9B CNY | 8.6 | 11 | |
| US |
|
Henry Schein Inc
NASDAQ:HSIC
|
9B USD | 15.6 | 22.6 | |
| CN |
|
Huadong Medicine Co Ltd
SZSE:000963
|
59.8B CNY | 12.5 | 16.2 | |
| KR |
|
Celltrion Healthcare Co Ltd
KOSDAQ:091990
|
12.2T KRW | 61.9 | 89.6 | |
| CN |
|
Sinopharm Group Co Ltd
HKEX:1099
|
61B HKD | 0.7 | 7.6 |
Market Distribution
| Min | 0.5 |
| 30th Percentile | 13.7 |
| Median | 17.9 |
| 70th Percentile | 25.3 |
| Max | 3 081.1 |
Other Multiples
Oriola Oyj
Glance View
Oriola Corp. engages in the provision of pharmaceutical, and health and well-being products retail and wholesale. The company is headquartered in Espoo, Etela-Suomen and currently employs 2,645 full-time employees. The company went IPO on 2006-07-03. The firm is engaged in the retail and wholesale of pharmaceuticals, acting as a channel between pharmaceutical manufacturers and consumers, primarily in Finland and Sweden. The firm's reporting segments are Consumer, Services, and Healthcare. Through its own pharmacies, the Company provides consumers with not only medicines and pharmaceutical advice but also a selection of healthcare consumer products and customer service. The firm is active through a number of subsidiaries located throughout Europe, including PharmaService OY, Oriola AB, Oriola Oyj, Farenta Oy, Kronans Droghandel Apotek AB and Svensk dos AB.
